Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Forsta AP Fonden

Forsta AP Fonden grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 384,500 shares of the biopharmaceutical company’s stock after purchasing an additional 19,600 shares during the period. Forsta AP Fonden’s holdings in Gilead Sciences were worth $26,381,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Gilbert & Cook Inc. boosted its holdings in shares of Gilead Sciences by 5.3% in the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 344 shares in the last quarter. Aveo Capital Partners LLC boosted its stake in Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock valued at $443,000 after purchasing an additional 435 shares in the last quarter. Cary Street Partners Investment Advisory LLC increased its position in shares of Gilead Sciences by 47.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 6,313 shares of the biopharmaceutical company’s stock valued at $511,000 after purchasing an additional 2,024 shares during the period. Jump Financial LLC raised its stake in shares of Gilead Sciences by 141.2% in the 4th quarter. Jump Financial LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 4,184 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Gilead Sciences by 4.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 231,819 shares of the biopharmaceutical company’s stock valued at $18,780,000 after buying an additional 10,577 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a research report on Monday. Finally, Truist Financial upped their price target on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $82.06.

Gilead Sciences Price Performance

NASDAQ GILD opened at $80.94 on Thursday. The company has a 50 day simple moving average of $74.82 and a 200-day simple moving average of $70.72. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The firm has a market capitalization of $100.77 billion, a price-to-earnings ratio of 224.83, a price-to-earnings-growth ratio of 2.73 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Equities research analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.81%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.